Effects of Cocoa Intake on Blood Pressure in Elderly Individuals With Mild Hypertension
Launched by UNIVERSITY OF COLOGNE · Jan 11, 2007
Trial Information
Current as of May 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects between the ages of 55 - 75 years in good general health with high normal blood pressure (between 130/80 and 140/90 mmHg) or mild hypertension (blood pressure between 140/90 and 160/100 mmHg)on no medication or nutritional supplements
- • Non-manual workers with a household income \> 20,000 €/year
- • Normal plasma lipids (total plasma cholesterol \< 6.18 mmol/L
- • LDL \< 4.11 mmol/L
- • HDL \> 0.9 mmol/L
- • Triacylglycerols \< 1.8 mmol/L) and normal plasma glucose (fasting plasma glucose 4.2-6.4 mmol/L).
- • If a subject's blood pressure exceeds 170/100 mmHg on a single visit, the subject will be withdrawn from the study and referred to appropriate antihypertensive therapy.
- Exclusion Criteria:
- Subjects are excluded if they have:
- • Cardiovascular diseases (other than hypertension)
- • Diabetes mellitus
- • Hyper-/dyslipidemia
- • Gastrointestinal diseases
- • Hepatic and renal disorders
- • Pulmonary diseases
- • Coagulopathy
- • Cancer
- • Psychiatric disorders
- • Alcohol or drug dependence
- • Seizure disorders
- • History of organ transplantation
- • Surgery within the last 12 months
- • Positive tests for HIV, hepatitis B or C.
- Subjects are excluded if they have:
- • A body-mass index of more than 27.5 or less than 18.5 kg/m2
- • Actively smoked tobacco within the last five years
- • Regularly use medications
- • Used any medication within the last two weeks before entry
- • Use vitamin, mineral or polyphenol supplements or functional food.
- • Subjects will be excluded if they are unable to give informed consent for all procedures; or subjects who are not capable or willing to appear for controlling visits.
About University Of Cologne
The University of Cologne, a prestigious institution located in Germany, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to design and conduct innovative studies aimed at improving patient care and health outcomes. With a focus on collaboration across various disciplines, the University of Cologne emphasizes rigorous scientific methodologies and ethical standards in its clinical research initiatives, contributing significantly to the global medical community and fostering the development of new therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cologne, , Germany
Patients applied
Trial Officials
Dirk Taubert
Principal Investigator
Department of Pharmacology, University of Cologne
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials